Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5653703 | The Journal of Emergency Medicine | 2017 | 7 Pages |
Abstract
The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran. As more clinical practice experience is gained with the agent and the remaining data on its use are released, clinicians can better guide the clinical use of idarucizumab. At present, there is currently not enough evidence for idarucizumab to be used as monotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Emergency Medicine
Authors
Luke PharmD, BCPS, Jason A. PharmD, BCPS, BCCCP, Calvin PharmD, BCPS, BCCCP,